2016 Fiscal Year Final Research Report
Development of novel therapeutic compounds for rheumatoid arthritis targeting CD81
| Project/Area Number |
26460165
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Shujitsu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 関節リウマチ / テトラスパニン / CD81 / シノビオリン / 炎症性サイトカイン / 滑膜細胞 |
|---|
| Outline of Final Research Achievements |
Screening of low MW compounds was performed for development of novel therpeutic compounds toward the treatment of rheumatoid arthritis targeting CD81, tetraspanin molecule. At first, cell binding screening was performed using SW982 cells. When anti-CD81 monoclonal antibodies and the compounds were added to cells, eight compounds were found to increase or decrease the binding of antibodies. Among them, three compounds were effective to decrease the expression of inflammatory cytokines and synoviolin.
|
| Free Research Field |
生化学・分子生物学
|
